We are all familiar with typical medication delivery systems, including tablets, syringes and suppositories; but did you know that since 1984, LTS has been developing technologically advanced, intelligent delivery system alternatives? It is all about drug delivery. Here at LTS, we develop and manufacture transdermal therapeutic systems or transdermal patches. The word “transdermal” originates from the Latin term ‘trans’ meaning through and the Greek term ‘derma’ meaning skin. That’s how our patches work:
they contain medications that enter the blood stream via absorption through the skin. This subject will be one of the main topics in our blog entries. We will also provide you with information about LTS’ other innovative technology: thin, quick dissolving films, or oral thin films (OTF). Much like transdermal patches, these films also contain medications. However, oral thin films are applied on the tongue or in the cheek pouch where they dissolve. By use of oral thin films, medication is delivered through the buccal or oral mucosa.
Our major milestones
Launch of an ondansetrone OTF for the treatment and prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy
Launch of the first ibuprofen patch, a local analgesic for the treatment of articular painful conditions, both traumatic and rheumatic.
Launch of a fentanyl OTF for the treatment of breakthrough pain in opioid therapy for chronic cancer pain.
Launch of the first cutaneous patch with a high concentrate of capsaicin (8 %) indicated for the management of neuropathic pain associated with postherpetic neuralgia.
Launch of the first transdermal patch for the treatment of Alzheimer’s disease
Launch of the first transdermal patch for the treatment of Parkinson’s disease
The first nicotine patch for smoking cessation is launched in the US
The first TTS matrix system from LTS achieves approval and is launched, a nitroglycerin patch.